ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
사이람자(라무시루맙) 시장 규모는 향후 몇 년간 강한 성장을 보일 것으로 예상됩니다. 예측 기간 동안의 성장은 임상 시험 증가, 암 검진 프로그램 확대, 치료 수요 증가, 환자 수 증가, 그리고 변화하는 치료 환경 등에 기인할 것으로 분석됩니다. 예측 기간의 주요 동향으로는 라무시루맙의 적용 확대, FDA 승인, 맞춤형 의약품에 대한 강조, 복합 의약품의 채택 증가, 제품 혁신 등이 있습니다.
암 발병률의 증가는 향후 몇 년 동안 사이람자(라무시루맙) 시장의 성장을 촉진할 것으로 예상됩니다. 암은 통제되지 않은 세포 성장과 다른 신체 부위로의 세포 확산이 특징인 질병의 그룹입니다. 암 발병률의 증가는 인구 고령화, 생활 습관, 환경 노출, 진단 기술의 발전, 유전적 요인 등 여러 요인에 기인합니다. 사이람자(라무시루맙)는 암 치료에 사용되어 혈관 내피 성장 인자 수용체 2(VEGFR-2)를 표적으로 억제하여 종양에 영양을 공급하는 혈관의 성장을 막고 암의 진행을 늦추는 데 도움이 됩니다. 예를 들어, 호주 보건 복지 연구소(Australian Institute of Health and Welfare)가 2024년 8월에 발표한 보고서에 따르면, 호주는 2034년까지 약 20만 9,000건의 새로운 암 진단 사례가 발생할 것으로 예상되며, 이는 2024년 추정치인 16만 9,000건에서 증가한 수치입니다. 이 증가는 인구 증가와 암 발생률 상승을 모두 반영합니다. 또한, 2024년까지 암이 호주 전체 사망자의 약 30%를 차지할 것으로 예상됩니다. 그 결과, 암 발병률의 증가가 사이람자(라무시루맙) 시장의 확장을 촉진하고 있습니다.
사이람자(라무시루맙) 시장의 주요 동향은 진행성 또는 전이성 암 환자의 치료를 개선하기 위한 혁신적인 약물 요법의 개발입니다. 간세포암(HCC)에 사용되는 라무시루맙과 같은 의약품은 특정 암 마커를 표적으로하여 종양 성장을 늦추고 생존율을 개선합니다. 예를 들어, 2022년 10월, 중국 바이오 제약 회사인 Innovent Biologics Inc.는 중국 국가 의약품 관리국(NMPA)이 알파-태아 단백질 수치가 400ng/mL 이상이고 이미 소라페닙을 투여받은 간세포암(HCC) 환자 치료에 대한 사이람자(라무시루맙)의 추가 신약 신청(sNDA)을 승인했다고 발표했습니다. 또한 사이람자는 파클리탁셀과 병용하여 진행성 또는 전이성 위암 또는 위식도 접합부(GEJ) 선암의 2차 치료제로 승인되어, 중국에서 이 적응증에 대해 승인된 최초이자 유일한 표적 의약품이 되었습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 바이오의약품 시장에서의 제품 특성
분자 유형
투여경로(ROA)
작용기전(MOA)
안전성과 유효성
제4장 시장 동향과 전략
제5장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염, 경기 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제6장 세계의 성장 분석과 전략 분석 프레임워크
세계의 사이람자(라무시루맙) : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 사이람자(라무시루맙) 시장 : 성장률 분석
세계의 사이람자(라무시루맙) 시장 실적 : 규모와 성장(2019-2024년)
세계의 사이람자(라무시루맙) 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 사이람자(라무시루맙) : 전체 시장 규모(TAM)
제7장 세계 시장의 가격 분석과 예측
제8장 시장 세분화
세계의 사이람자(라무시루맙) 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
100mg/box
500mg/box
세계의 사이람자(람실마브) 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
진행성 위암
GEJ 선암
비소세포 폐암
전이성 대장암(mCRC)
간세포암(HCC)
세계의 사이람자(람실마브) 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
암 치료 센터
외래수술센터(ASC)
연구기관
제9장 임상적응증 세계 시장 역학
약의 부작용
임상적응증의 발병률과 유병률
제10장 지역별, 국가별 분석
세계의 사이람자(라무시루맙) 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 사이람자(라무시루맙) 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 한국 시장
제17장 서유럽 시장
제18장 영국 시장
제19장 독일 시장
제20장 프랑스 시장
제21장 동유럽 시장
제22장 북미 시장
제23장 미국 시장
제24장 캐나다 시장
제25장 남미 시장
제26장 중동 시장
제27장 아프리카 시장
제28장 경쟁 구도와 기업 프로파일
사이람자(라무시루맙) 시장 : 경쟁 구도
사이람자(라무시루맙) 시장 : 기업 프로파일
Eli Lilly and Company
제29장 세계 시장 : 파이프라인 분석
제30장 세계 시장 경쟁 벤치마킹과 대시보드
제31장 주요 인수합병(M&A)
제32장 최근 시장 동향
제33장 시장의 잠재력이 높은 국가, 전략
사이람자(라무시루맙) 시장(2029년) : 새로운 기회를 제공하는 국가
사이람자(라무시루맙) 시장(2029년) : 새로운 기회를 제공하는 부문
사이람자(라무시루맙) 시장(2029년) : 성장 전략
시장 동향에 의한 전략
경쟁 전략
제34장 부록
HBR
영문 목차
영문목차
Cyramza (ramucirumab) is a monoclonal antibody used in cancer treatment. It works by targeting and inhibiting the vascular endothelial growth factor receptor 2 (VEGFR-2), which helps prevent tumor blood vessel formation. Cyramza is commonly used to treat various cancers, including gastric, colorectal, and lung cancer.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary types of cyramza (ramucirumab) are 100mg/Box and 500mg/Box. The 100mg/Box refers to the packaging size of Cyramza, with each box containing 100 mg of the drug. This smaller packaging is typically used for patients requiring a lower dose of the medication, facilitating easier distribution and use in different medical settings. Cyramza has various applications in the treatment of advanced gastric cancer, GEJ adenocarcinoma, non-small cell lung carcinoma, metastatic colorectal cancer (MCRC), and hepatocellular carcinoma (HCC). It is utilized by end users such as hospitals, cancer treatment centers, ambulatory surgical centers, and research institutes.
The cyramza (ramucirumab) market research report is one of a series of new reports from The Business Research Company that provides Cyramza (Ramucirumab) market statistics, including the Cyramza (Ramucirumab) industry's global market size, regional shares, competitors with a Cyramza (Ramucirumab) market share, detailed Cyramza (Ramucirumab) market segments, market trends and opportunities, and any further data you may need to thrive in the Cyramza (Ramucirumab) industry. This Cyramza (Ramucirumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The cyramza (ramucirumab) market size is expected to see strong growth in the next few years. It will grow to $1,686.3 million in 2029 at a compound annual growth rate (CAGR) of 6%. The growth in the forecast period can be attributed to increasing clinical trials, increasing cancer screening programs, demand for treatment, growing number of patients, and changing li. Major trends in the forecast period include expanding application of ramucirumab, FDA approvals, emphasis on personalized medicine, growing adoption of combination medicines, and product innovation.
The increasing incidence of cancer is expected to drive the growth of the cyramza (ramucirumab) market in the coming years. Cancer is a group of diseases marked by uncontrolled cell growth and the spread of cells to other body parts. The rise in cancer cases is due to factors like an aging population, lifestyle choices, environmental exposures, improved detection, and genetic factors. Cyramza (ramucirumab) is used in cancer treatment to target and inhibit the vascular endothelial growth factor receptor 2 (VEGFR-2), which helps prevent the growth of blood vessels that nourish tumors and slow cancer progression. For example, according to a report by the Australian Institute of Health and Welfare published in August 2024, Australia is projected to have around 209,000 new cancer diagnoses by 2034, up from an estimated 169,000 in 2024. This increase reflects both the growing population and rising cancer rates. Furthermore, cancer is expected to account for approximately 30% of all deaths in the country by 2024. As a result, the growing incidence of cancer is driving the expansion of the cyramza (ramucirumab) market.
A key trend in the cyramza (ramucirumab) market is the development of innovative drug therapies aimed at improving treatment for patients with advanced or metastatic cancer. Drugs like ramucirumab for hepatocellular carcinoma (HCC) target specific cancer markers to slow tumor growth and improve survival rates. For instance, in October 2022, Innovent Biologics Inc., a Chinese biopharmaceutical company, announced that China's National Medical Products Administration (NMPA) approved the supplemental New Drug Application (sNDA) for Cyramza (ramucirumab) in treating patients with hepatocellular carcinoma (HCC) who have an alpha-fetoprotein level of >=400 ng/mL and have already received sorafenib. Additionally, Cyramza was approved in combination with paclitaxel as a second-line treatment for advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, becoming the first and only targeted drug approved for this indication in China.
In March 2022, Innovent Biologics Inc. partnered with Eli Lilly and Company to develop and commercialize cutting-edge cancer therapies in China. This partnership aims to combine the strengths of both companies to advance innovative cancer treatments, starting with the monoclonal antibody Cyramza (ramucirumab), and enhance cancer treatment by targeting tumor growth through angiogenesis inhibition. Eli Lilly and Company, a US-based pharmaceutical company, manufactures Cyramza (ramucirumab).
The key player operating in the cyramza (ramucirumab) market is Eli Lilly and Company.
North America was the largest region in the cyramza (ramucirumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cyramza (ramucirumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the cyramza (ramucirumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The cyramza (ramucirumab) market consists of sales of cyramza (ramucirumab) iv infusion and combination therapy formulations. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cyramza (Ramucirumab) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on cyramza (ramucirumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for cyramza (ramucirumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cyramza (ramucirumab) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: 100mg/Box; 500mg/Box
2) By Application: Advanced Gastric Cancer; GEJ Adenocarcinoma; Non-small Cell Lung Carcinoma; Metastatic Colorectal Cancer (mCRC); Hepatocellular Carcinoma (HCC)
3) By End-User: Hospitals; Cancer Treatment Centers; Ambulatory Surgical Centers; Research Institutes
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Cyramza (Ramucirumab) Market Characteristics
3. Cyramza (Ramucirumab) Market Biologic Drug Characteristics
3.1. Molecule Type
3.2. Route Of Administration (ROA)
3.3. Mechanism Of Action (MOA)
3.4. Safety And Efficacy
4. Cyramza (Ramucirumab) Market Trends And Strategies
5. Cyramza (Ramucirumab) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
6. Global Cyramza (Ramucirumab) Growth Analysis And Strategic Analysis Framework
6.1. Global Cyramza (Ramucirumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.2. Analysis Of End Use Industries
6.3. Global Cyramza (Ramucirumab) Market Growth Rate Analysis
6.4. Global Cyramza (Ramucirumab) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
6.5. Global Cyramza (Ramucirumab) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
6.6. Global Cyramza (Ramucirumab) Total Addressable Market (TAM)
7. Global Cyramza (Ramucirumab) Market Pricing Analysis & Forecasts
8. Cyramza (Ramucirumab) Market Segmentation
8.1. Global Cyramza (Ramucirumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
100mg/Box
500mg/Box
8.2. Global Cyramza (Ramucirumab) Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Advanced Gastric Cancer
GEJ Adenocarcinoma
Non-small Cell Lung Carcinoma
Metastatic Colorectal Cancer (mCRC)
Hepatocellular Carcinoma (HCC)
8.3. Global Cyramza (Ramucirumab) Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Cancer Treatment Centers
Ambulatory Surgical Centers
Research Institutes
9. Global Cyramza (Ramucirumab) Market Epidemiology Of Clinical Indications
9.1. Drug Side Effects
9.2. Incidence And Prevalence of Clinical Indications
10. Cyramza (Ramucirumab) Market Regional And Country Analysis
10.1. Global Cyramza (Ramucirumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. Global Cyramza (Ramucirumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
